Home | Find A Doctor | Contact Us


Multicenter, non-randomized, prospective study for the treatment of non-melanoma skin cancer (squamous cell cancer and basal cell cancer) using Xoft Axxent Electronic Brachytherapy Treatment System as the primary treatment for NMSC

Principal Investigator: Kenneth Hu, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai West


Continuum Cancer Research Program
(212) 844-6286


The purpose of the study is to collect data on the patient population with NMSC who are treated with the Xoft Axxent electronic brachytherapy system. Brachytherapy has the advantage of delivering a high dose to the tumor while sparing the surrounding normal tissues.
With proper case selection and delivery technique, high-dose rate (HDR) brachytherapy allows short treatment times, and can be performed on an outpatient basis.

Eligibility and Treatment Plan:
To qualify for this study, patients must meet certain criteria, including but not limited to:

Study patients must have pathological diagnosis confirmed of squamous cell or basal cell carcinoma with histopathological Grade of G1 (well differentiated), G2 (moderately differentiated) or Gx (Not assessed in report).

Please call the Continuum Cancer Research Program: 212-844-6286 for more information.




Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System